HTR6
ENSG00000158748
Target class
GPCR
Chromosome
1
Approved drugs
3
Clinical candidates (approved and in development)
8
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- HTR6
- Gene name
- 5-hydroxytryptamine receptor 6
- Gene symbol
- HTR6
- Protein name
- 5-hydroxytryptamine receptor 6 (5-HT-6) (5-HT6) (Serotonin receptor 6)
- 5-HT6
- 5-HT6R
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 5
- Highest tissue expression
- 4.45
- Tissue specificity (Gini)
- 0.79
- Tissue specificity (tau)
- 0.943
- KEGG gene identifiers
- hsa:3362
- Protein interaction confidence
- 0.887385
- Protein interaction partners
- 13
- R-HSA-390666
- R-HSA-418555
- End position
- 19680966
- Start position
- 19664875
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 37327704
- PubMed 35714614
- PubMed 36989299
- Tissue specificity (tau)
- 0.943439
- Expression inequality (Gini)
- 0.790405
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 4.45
- Brain - Caudate (basal ganglia)
- 3.11
- Brain - Putamen (basal ganglia)
- 2.06
- Brain - Cortex
- 1.77
- Brain - Frontal Cortex (BA9)
- 1.6
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)4.45
- Brain - Caudate (basal ganglia)3.11
- Brain - Putamen (basal ganglia)2.06
- Brain - Cortex1.77
- Brain - Frontal Cortex (BA9)1.6
- Brain - Anterior cingulate cortex (BA24)0.76
- Brain - Hypothalamus0.42
- Testis0.38
- Cervix - Endocervix0.27
- Cells - EBV-transformed lymphocytes0.24
- Pituitary0.23
- Brain - Hippocampus0.23
- Brain - Amygdala0.21
- Cervix - Ectocervix0.12
- Colon - Sigmoid0.1
- Prostate0.1
- Vagina0.1
- Small Intestine - Terminal Ileum0.09
- Uterus0.09
- Brain - Substantia nigra0.08
- Skin - Not Sun Exposed (Suprapubic)0.08
- Spleen0.08
- Skin - Sun Exposed (Lower leg)0.08
- Artery - Tibial0.08
- Artery - Aorta0.08
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007192
- GO:0007268
- GO:0032008
Cellular components
- GO:0005886
- GO:0004969
- GO:0004993
- GO:0005515
reduced appetite
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351weight loss
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351
receptor binding
Studies
- biochemical: NVS_GPCR_h5HT6, is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT6 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (1,639)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
- A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
Drugs (45)
- Amisulpride Serotonin (5-HT) receptor antagonist
- Amitriptyline
- Amoxapine
- Bromocriptine
- Capeserod
- Cerlapirdine Serotonin 6 (5-HT6) receptor antagonist
- Cerlapirdine hydrochloride Serotonin 6 (5-HT6) receptor antagonist
- Chlorpromazine
- Clozapine
- Cyproheptadine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Donitriptan
- Duloxetine
- Ergotamine
- Fluperlapine
- Fluphenazine
- Idalopirdine Serotonin 6 (5-HT6) receptor antagonist
- Iloperidone
- Intepirdine Serotonin 6 (5-HT6) receptor antagonist